Publications by authors named "K Kryeziu"

Background: Co-occurring mutations in pairs of genes can pinpoint clinically relevant subgroups of cancer. Most colorectal cancers (CRCs) are microsatellite stable (MSS) and have few frequent mutations. Large patient cohorts and broad genomic coverage are needed for comprehensive co-mutation profiling.

View Article and Find Full Text PDF

Necrotizing fasciitis (NF) is a rare, dangerous, potentially fatal infectious disease of soft tissue. The treatment consists of antibiotic therapy, surgical debridement and subsequent reconstruction. Hyperbaric oxygen (HBO) therapy has been applied in NF patients recently, so our aim was to gather the findings and outcomes for HBO therapy.

View Article and Find Full Text PDF

Intercellular communication via gap junctions has a fundamental role in regulating cell growth and tissue homeostasis, and its dysregulation may be involved in cancer development and radio- and chemotherapy resistance. Connexin43 (Cx43) is the most ubiquitously expressed gap junction channel protein in human tissues. Emerging evidence indicates that dysregulation of the sorting of Cx43 to lysosomes is important in mediating the loss of Cx43-based gap junctions in cancer cells.

View Article and Find Full Text PDF

Gap junctions are specialized regions of the plasma membrane containing clusters of channels that provide for the diffusion of ions and small molecules between adjacent cells. A fundamental role of gap junctions is to coordinate the functions of cells in tissues. Cancer pathogenesis is usually associated with loss of intercellular communication mediated by gap junctions, which may affect tumor growth and the response to radio- and chemotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Small-molecule EGFR inhibitors have improved survival rates in EGFR-mutated lung cancer, but they often cause severe side effects and resistance.
  • A new prodrug, KP2334, selectively activates in tumor areas with low oxygen levels, releasing a novel EGFR inhibitor, KP2187, designed to work effectively in those regions.
  • Research shows that KP2187 has similar binding and inhibitory effects on EGFR as established drugs like erlotinib and gefitinib, and it also works well in combination with VEGFR inhibitors, suggesting it could reduce toxicity in combination therapies.
View Article and Find Full Text PDF